1.5314

1.60% -0.0286

Aldeyra Therapeutics Inc (ALDX)

Overview News Price History Option Chain Financials Discussions Forecast

Aldeyra Therapeutics Inc stock is traded at $1.5314, with a volume of 559.09K. It is down -1.60% in the last 24 hours and down -9.17% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Previous Close:

$1.56

Open:

$1.55

24h Volume:

559.09K

Relative Volume:

0.42

Market Cap:

$92.30M

Revenue:

Net Income/Loss:

$-27.37M

P/E Ratio:

-3.3642

EPS:

-0.4552

Net Cash Flow:

$-25.99M

1W Performance:

+1.66%

1M Performance:

-9.17%

6M Performance:

-70.19%

1Y Performance:

-71.52%

1-Day Range:

$1.525

$1.58

1-Week Range:

$1.44

$1.58

52-Week Range:

$1.07

$6.175

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name

Aldeyra Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

781-761-4904

Address

131 HARTWELL AVENUE, LEXINGTON, MA

Employee

Twitter

@aldeyraaldx

Next Earnings Date

2026-08-06

Latest SEC Filings

ALDX's Discussions on Twitter

Compare ALDX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALDX Aldeyra Therapeutics Inc	1.53	94.11M	0	-27.37M	-25.99M	-0.4552
VRTX Vertex Pharmaceuticals Inc	515.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.22	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.16	39.31B	5.76B	514.49M	1.10B	4.4813

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform
Apr-02-24	Resumed	H.C. Wainwright	Buy
Apr-27-22	Resumed	H.C. Wainwright	Buy
Feb-08-21	Initiated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Oct-30-20	Initiated	Jefferies	Buy
Oct-16-20	Initiated	BTIG Research	Buy
Sep-22-20	Initiated	Alliance Global Partners	Buy
May-12-20	Initiated	Oppenheimer	Outperform
Dec-04-18	Initiated	Citigroup	Buy
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy
Sep-26-16	Initiated	H.C. Wainwright	Buy
Jul-01-16	Initiated	Stifel	Buy
Jul-01-15	Initiated	Canaccord Genuity	Buy
Mar-25-15	Initiated	Chardan Capital Markets	Buy
Mar-20-15	Reiterated	H.C. Wainwright	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy
Jun-19-14	Initiated	Aegis Capital	Buy

View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

Aug 15, 2026

Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 12, 2026

Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan

Aug 12, 2026

ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 12, 2026

Aug 11, 2026

ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 11, 2026

Aug 09, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 09, 2026

Aug 07, 2026